2023-508638-32-00CompletedPhase 1
Intermittent ibrutinib in chronic lymphocytic leukemia
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Nov 2023
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 9 Oct 2023
- Start date
- 6 Apr 2018
- Lead sponsor
- Karolinska University Hospital
- Diseases
- Chronic lymphocytic leukaemia
- EU CT number
- 2023-508638-32-00
- EudraCT number
- 2017-001990-17
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 50
- 9 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (9)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Olavs hospital HF | Trondheim | Norway | Completed |
| Region Dalarna | Falun | Sweden | Completed |
| Region Gaevleborg | Gavle | Sweden | Completed |
| Sahlgrenska University Hospital-Vastra Gotalandsregionen | Gothenburg | Sweden | Completed |
| Lund University Hospital | Lund | Sweden | Completed |
| Region Oerebro Laen | Orebro | Sweden | Completed |
| Karolinska University Hospital | Solna | Sweden | Completed |
| Norrlands University Hospital | Umeå | Sweden | Completed |
| Uppsala University Hospital | Uppsala | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.